Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Weight loss

Phase 3Small molecule

UUniversity of Texas Southwestern Medical Center

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Exercise TrainingRecruiting

Exercise TrainingPhase 3

Recruiting

Timeline

Expected Milestones

Q4 2026

Phase 2/3Recruiting

Exercise Training

NCT07223242

Clinical

Trials by Indication[1]

Exercise Training1 trial

Tailored Exercise Training Study Among Adults With HFpEF

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2/3·NCT07223242·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Weight loss. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Weight loss compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Weight loss. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Texas Southwestern Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Texas Southwestern Medical Center

Related News